Search

Your search keyword '"Feugier, A."' showing total 2,707 results
Start Over Author "Feugier, A."
2,707 results on '"Feugier, A."'

201. Baseline PET Metabolic Tumor Volume Predicts Outcome in Advanced Follicular Lymphoma Patients Who Received First-Line Immunochemotherapy but Not Those Treated with Lenalidomide-Rituximab in the Phase III Relevance Study

Author

Cottereau, Anne Ségolène, primary, Rebaud, Louis, additional, Trotman, Judith, additional, Feugier, Pierre, additional, Nastoupil, Loretta J., additional, Bachy, Emmanuel, additional, Flinn, Ian W., additional, Haioun, Corinne, additional, Ysebaert, Loic, additional, Bartlett, Nancy L., additional, Tilly, Hervé, additional, Casasnovas, René-Olivier, additional, Ricci, Romain, additional, Portugues, Cedric, additional, Buvat, Irène, additional, Meignan, Michel, additional, and Morschhauser, Franck, additional

Published
2022
Full Text
View/download PDF

202. A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

Author

Michallet, Anne-Sophie, primary, Letestu, Rémi, additional, Le Garff-Tavernier, Magali, additional, Aanaei, Carmen, additional, Ticchioni, Michel, additional, Dilhuydy, Marie-Sarah, additional, Morisset, Stephane, additional, Rouille, Valérie, additional, Mahé, Béatrice, additional, Laribi, Kamel, additional, Villemagne, Bruno, additional, Ferrant, Emmanuelle, additional, Tournilhac, Olivier, additional, Delmer, Alain, additional, Portois, Christelle, additional, Molina, Lysiane, additional, Leblond, Véronique, additional, Tomowiak, Cécile, additional, de Guibert, Sophie, additional, Orsini, Frederique, additional, Banos, Anne, additional, Carassou, Philippe, additional, Cartron, Guillaume, additional, Fornecker, Luc Mathieu, additional, Ysebaert, Loic, additional, Dartigeas, Caroline, additional, Truchan, Margot, additional, Vilque, Jean-Pierre, additional, Aurran Schleinitz, Therese, additional, Florence, Cymbalista, additional, Leprêtre, Stéphane, additional, Lévy, Vincent, additional, Nguyen Khac, Florence, additional, and Feugier, Pierre, additional

Published
2022
Full Text
View/download PDF

203. Selinexor in Combination with R-GDP for Patients with Relapsed/Refractory B-Cell Lymphoma: Final Results of 18 Patients Treated at RP2D of Selinexor in the Selinda Phase Ib Lysa Study

Author

Maerevoet, Marie, primary, Casasnovas, Olivier, additional, Cartron, Guillaume, additional, Morschhauser, Franck, additional, Thieblemont, Catherine, additional, Bouabdallah, Kamal, additional, Feugier, Pierre, additional, Szablewski, Vanessa, additional, Becker, Stéphanie, additional, and Tilly, Hervé, additional

Published
2022
Full Text
View/download PDF

204. Evolutionary History of Transformation from Chronic Lymphocytic Leukemia to Richter Syndrome

Author

Parry, Erin Michelle, primary, Guieze, Romain, additional, Leshchiner, Ignaty, additional, Johnson, Connor, additional, Tausch, Eugen, additional, Parikh, Sameer A., additional, Lemvigh, Camilla K, additional, Broséus, Julien, additional, Hergalant, Sébastien, additional, Messer, Connor, additional, Utro, Filippo, additional, Levovitz, Chaya, additional, Rhrissorrakrai, Kahn, additional, Li, Liang, additional, Li, Shuqiang, additional, Fell, Geoffrey G, additional, Redd, Robert A., additional, Lin, Ziao, additional, Knisbacher, Binyamin A., additional, Schneider, Christof, additional, Fernandes, Stacey M., additional, Hess, Julian M., additional, Rassenti, Laura Z., additional, Kipps, Thomas J., additional, Jain, Nitin, additional, Wierda, William G., additional, Cymbalista, Florence, additional, Feugier, Pierre, additional, Kay, Neil E., additional, Livak, Kenneth J, additional, Danysh, Brian P, additional, Stewart, Chip, additional, Neuberg, Donna S., additional, Davids, Matthew S., additional, Brown, Jennifer R., additional, Parida, Laxmi, additional, Stilgenbauer, Stephan, additional, Getz, Gad, additional, and Wu, Catherine J., additional

Published
2022
Full Text
View/download PDF

205. ZNF683 (Hobit) Marks a CD8+ T Cell Population Associated with Anti-Tumor Immunity Following Anti-PD-1 Therapy for Richter Syndrome

Author

Lemvigh, Camilla K, primary, Parry, Erin Michelle, additional, Deng, Stephanie L, additional, Dangle, Nathan J, additional, Ruthen, Neil, additional, Knisbacher, Binyamin A., additional, Broséus, Julien, additional, Hergalant, Sébastien, additional, Guieze, Romain, additional, Li, Shuqiang, additional, Yin, Shanye, additional, Huang, Teddy, additional, Livak, Kenneth J, additional, Getz, Gad, additional, Neuberg, Donna S., additional, Feugier, Pierre, additional, Kharchenko, Peter, additional, Wierda, William G., additional, Olsen, Lars Rønn, additional, Jain, Nitin, additional, and Wu, Catherine J., additional

Published
2022
Full Text
View/download PDF

206. Axicabtagene Ciloleucel As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Primary Analysis of Alycante, a Phase 2 Lysa Study

Author

Houot, Roch, primary, Bachy, Emmanuel, additional, Cartron, Guillaume, additional, Gros, François-Xavier, additional, Morschhauser, Franck, additional, Oberic, Lucie, additional, Gastinne, Thomas, additional, Feugier, Pierre, additional, Dulery, Remy, additional, Thieblemont, Catherine, additional, Joris, Magalie, additional, Llamas-Gutierrez, Francisco, additional, Itti, Emmanuel, additional, Menard, Cedric, additional, Al-Tabaa, Yassine, additional, Bailly, Clement, additional, Delfau, Marie-Helene, additional, Laurent, Camille, additional, and Lemonnier, Francois, additional

Published
2022
Full Text
View/download PDF

207. Blinatumomab for Patients with Richter Syndrome: Final Results of the Phase 2 Blinart Trial from the Filo Group

Author

Guieze, Romain, primary, Ysebaert, Loic, additional, Roos-Weil, Damien, additional, Fornecker, Luc-Matthieu, additional, Ferrant, Emmanuelle, additional, Molina, Lysiane, additional, Aurran-Schleinitz, Thérèse, additional, Clavert, Aline, additional, de Guibert, Sophie, additional, Michallet, Anne-Sophie, additional, Saad, Alain, additional, Drenou, Bernard, additional, Quittet, Philippe, additional, Hivert, Benedicte, additional, Laribi, Kamel, additional, Gay, Julie, additional, Broséus, Julien, additional, Rouille, Valérie, additional, Schwartz, David, additional, Pereira, Bruno, additional, Delmer, Alain, additional, and Feugier, Pierre, additional

Published
2022
Full Text
View/download PDF

208. Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Author

Quinquenel, Anne, primary, Letestu, Rémi, additional, Le Garff-Tavernier, Magali, additional, Subtil, Fabien, additional, Aurran-Schleinitz, Therese, additional, Laribi, Kamel, additional, Cymbalista, Florence, additional, Levy, Vincent, additional, Simon, Laurence, additional, Roos-Weil, Damien, additional, Leblond, Véronique, additional, Dilhuydy, Marie-Sarah, additional, Dartigeas, Caroline, additional, Tomowiak, Cecile, additional, Guieze, Romain, additional, Tournilhac, Olivier, additional, Ferrant, Emmanuelle, additional, de Guibert, Sophie, additional, Feugier, Pierre, additional, Merabet, Fatiha, additional, Lepretre, Stephane, additional, Carassou, Philippe, additional, Gay, Julie, additional, Hivert, Bénédicte, additional, Fornecker, Luc Mathieu, additional, Dupuis, Jehan, additional, Molina, Lysiane, additional, Villemagne, Bruno, additional, Cartron, Guillaume, additional, Drenou, Bernard, additional, Mahé, Béatrice, additional, Benbrahim, Omar, additional, Cahu, Xavier, additional, Portois, Christelle, additional, Ysebaert, Loic, additional, Nguyen Khac, Florence, additional, Rouille, Valérie, additional, Delmer, Alain, additional, and Michallet, Anne-Sophie, additional

Published
2022
Full Text
View/download PDF

209. Age-Related Immune Cell Dynamics Influences Outcomes after Allogeneic Hematopoietic Cell Transplantation

Author

Alizee, Jandin, primary, Pochon, Cecile, additional, Campidelli, Arnaud, additional, D'Aveni, Maud, additional, Kicki, Celine, additional, Mbuyi, Tshinguta, additional, De Carvalho Bittencourt, Marcelo, additional, Chastagner, Pascal, additional, Feugier, Pierre, additional, Pagliuca, Simona, additional, and Rubio, Marie Thérèse, additional

Published
2022
Full Text
View/download PDF

211. Pesticide-Free Robotic Control of Aphids as Crop Pests

Author

Lacotte, Virginie, primary, NGuyen, Toan, additional, Sempere, Javier Diaz, additional, Novales, Vivien, additional, Dufour, Vincent, additional, Moreau, Richard, additional, Pham, Minh Tu, additional, Rabenorosoa, Kanty, additional, Peignier, Sergio, additional, Feugier, François G., additional, Gaetani, Robin, additional, Grenier, Thomas, additional, Masenelli, Bruno, additional, da Silva, Pedro, additional, Heddi, Abdelaziz, additional, and Lelevé, Arnaud, additional

Published
2022
Full Text
View/download PDF

212. Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma

Author

Morschhauser, Franck, primary, Nastoupil, Loretta, additional, Feugier, Pierre, additional, Schiano de Colella, Jean-Marc, additional, Tilly, Hervé, additional, Palomba, Maria Lia, additional, Bachy, Emmanuel, additional, Fruchart, Christophe, additional, Libby, Edward N., additional, Casasnovas, Rene-Olivier, additional, Flinn, Ian W., additional, Haioun, Corinne, additional, Maisonneuve, Hervé, additional, Ysebaert, Loic, additional, Bartlett, Nancy L., additional, Bouabdallah, Kamal, additional, Brice, Pauline, additional, Ribrag, Vincent, additional, Le Gouill, Steven, additional, Daguindau, Nicolas, additional, Guidez, Stéphanie, additional, Pica, Gian Matteo, additional, García-Sancho, Alejandro Martín, additional, López-Guillermo, Armondo, additional, Larouche, Jean-François, additional, Ando, Kiyoshi, additional, Gomes da Silva, Maria, additional, André, Marc, additional, Kalung, Wu, additional, Sehn, Laurie H., additional, Izutsu, Koji, additional, Cartron, Guillaume, additional, Gkasiamis, Argyrios, additional, Crowe, Russell, additional, Xerri, Luc, additional, Fowler, Nathan H., additional, and Salles, Gilles, additional

Published
2022
Full Text
View/download PDF

225. Characteristics of chronic lymphocytic leukemia patients achieving 5+ years of remission after FC‐based first‐line treatment: Retrospective observations from the FILO group

Author

Guillermin, Yann, Herbaux, Charles, Subtil, Fabien, Aurran‐Schleinitz, Thérèse, Cymbalista, Florence, Letestu, Remi, Leprêtre, Stéphane, Vaudaux, Sandrine, Laribi, Kamel, Leblond, Véronique, Defoi, Yasmina, Benchikh, Raouf, Salles, Gilles, Godmer, Pascal, Jardel, Henry, Vallais, Fréderic, Feugier, Pierre, Orsini, Frédérique, Pegourié, Brigitte, Lévy, Vincent, and Michallet, Anne‐Sophie

Published
2018
Full Text
View/download PDF

228. Success of a weight loss plan for overweight dogs: The results of an international weight loss study.

Author

John Flanagan, Thomas Bissot, Marie-Anne Hours, Bernabe Moreno, Alexandre Feugier, and Alexander J German

Subjects
Medicine, Science
Abstract

Obesity is a global concern in dogs with an increasing prevalence, and effective weight loss solutions are required that work in different geographical regions. The main objective was to conduct an international, multi-centre, weight loss trial to determine the efficacy of a dietary weight loss intervention in obese pet dogs.A 3-month prospective observational cohort study of weight loss in 926 overweight dogs was conducted at 340 veterinary practices in 27 countries. Commercially available dry or wet weight loss diets were used, with the initial energy allocation being 250-335 kJ/kg target body weight0.75/day (60-80 kcal/kg target body weight0.75/day) depending on sex and neuter status. The primary outcome measure was percentage weight loss; the main secondary outcomes were changes in activity, quality of life, and food-seeking behaviour, which were subjectively determined from owner descriptions.At baseline, median (range) age was 74 (12 to 193) months and median body condition score was 8 (range 7-9). 896 of the 926 dogs (97%) lost weight, with mean weight loss being 11.4 ±5.84%. Sexually intact dogs lost more weight than neutered dogs (P = 0.001), whilst female dogs lost more weight than male dogs (P = 0.007), with the difference being more pronounced in North and South American dogs (median [Q1, Q3]: female: 11.5% [8.5%, 14.5%]; male: 9.1% [6.3%, 12.1%], P = 0.053) compared with those from Europe (female: 12.3% [8.9%, 14.9%]; male: 10.9% [8.6%, 15.4%]). Finally, subjective scores for activity (P

Published
2017
Full Text
View/download PDF

229. Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma

Author

Esther Hazane Leroyer, Caroline Ziegler, Charline Moulin, Arnaud Campidelli, Caroline Jacquet, Marie Thérèse Rubio, Pierre Feugier, and Simona Pagliuca

Subjects
General Medicine
Abstract

Despite years of clinical progress which made Hodgkin lymphoma (HL) one of the most curable malignancies with conventional chemotherapy, refractoriness and recurrence may still affect up to 20–30% of patients. The revolution brought by the advent of immunotherapy in all kinds of neoplastic disorders is more than evident in this disease because anti-CD30 antibodies and checkpoint inhibitors have been able to rescue patients previously remaining without therapeutic options. Autologous hematopoietic cell transplantation still represents a significant step in the treatment algorithm for chemosensitive HL; however, the possibility to induce complete responses after allogeneic transplant procedures in patients receiving reduced-intensity conditioning regimens informs on its sensitivity to immunological control. Furthermore, the investigational application of adoptive T cell transfer therapies paves the way for future indications in this setting. Here, we seek to provide a fresh and up-to-date overview of the new immunotherapeutic agents dominating the scene of relapsed/refractory HL. In this optic, we will also review all the potential molecular mechanisms of tumor resistance, theoretically responsible for treatment failures, and we will discuss the place of allogeneic stem cell transplantation in the era of novel therapies.

Published
2022

230. Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R

Author

Franck, Morschhauser, Loretta, Nastoupil, Pierre, Feugier, Jean-Marc, Schiano de Colella, Hervé, Tilly, Maria Lia, Palomba, Emmanuel, Bachy, Christophe, Fruchart, Edward N, Libby, Rene-Olivier, Casasnovas, Ian W, Flinn, Corinne, Haioun, Hervé, Maisonneuve, Loic, Ysebaert, Nancy L, Bartlett, Kamal, Bouabdallah, Pauline, Brice, Vincent, Ribrag, Steven, Le Gouill, Nicolas, Daguindau, Stéphanie, Guidez, Gian Matteo, Pica, Alejandro Martín, García-Sancho, Armondo, López-Guillermo, Jean-François, Larouche, Kiyoshi, Ando, Maria, Gomes da Silva, Marc, André, Wu, Kalung, Laurie H, Sehn, Koji, Izutsu, Guillaume, Cartron, Argyrios, Gkasiamis, Russell, Crowe, Luc, Xerri, Nathan H, Fowler, and Gilles, Salles

Subjects
Survival Rate, Antineoplastic Combined Chemotherapy Protocols, Humans, Neoplasms, Second Primary, Rituximab, Lenalidomide, Lymphoma, Follicular
Published
2022

233. Prolonged in‐hospital stay and higher mortality after Covid‐19 among patients with <scp>non‐Hodgkin</scp> lymphoma treated with B‐cell depleting immunotherapy

Author

Roberta Di Blasi, Laure Philippe, Thomas Hueso, Catherine Thieblemont, Karine Lacombe, Bénédicte Deau Fischer, Serge Bologna, Caroline Besson, Guillemette Fouquet, Sylvain Choquet, Milena Kohn, Rémy Duléry, Carole Soussain, Bernard Drenou, Pierre Feugier, Etienne Daguindau, Marc Delord, Nicolas Noel, Adrien Chauchet, Sylvain Lamure, Sandra Malak, Cédric Rossi, Bertrand Joly, Guillaume Cartron, Yassine Taoufik, Service d'hématologie clinique et de thérapie cellulaire [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Institut de Génétique Moléculaire de Montpellier (IGMM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Département d’Hématologie Clinique [CHRU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier de Versailles André Mignot (CHV), Service d'hématologie-oncologie adultes, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université de Paris (UP), Service d'hématologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Institut Gustave Roussy (IGR), Service d'Hématologie Clinique (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Groupe hospitalier de la région de Mulhouse Sud-Alsace (GHRMSA), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Curie [Saint-Cloud], Service d'Hématologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Service d'Hématologie clinique [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre d'Oncologie de Gentilly, Centre Hospitalier Sud Francilien, CH Evry-Corbeil, Service d'Hématologie [CH Annecy], CH Annecy, Hôpital Bicêtre, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Roche, Takeda Pharmaceutical Company, TPC, We thank all the clinicians and patients in the participating centers for their contributions to this multicenter study. We are grateful to the Centre Hospitalier de Versailles, in particular Philippe Rousselot and Laure Morisset for promoting the research and for supporting the editing. We thank France Lymphome Espoir for reviewing the study material, LYSA for discussions on the design of this study, and Sophie Rigaudeau and C?cile Laur?ana for their contribution to the collection of the cases., Rémy Duléry reports personal fees from Takeda, Novartis, and Biotest and non‐financial support from Gilead outside the submitted work. Roberta Di Blasi reports personal fees from Gilead and Novartis outside the submitted work. Serge Bologna reports personal fees from Janssen and Roche outside the submitted work. Guillaume Cartron reports personal fees from Roche, Celgene, Sanofi, Gilead, Janssen, and Abbvie outside the submitted work. Karine Lacombe reports personal fees and non‐financial support from Gilead, MSD, Abbvie, ViiV Healthcare, and Janssen outside the submitted work. Caroline Besson reports research funding from Roche and non‐financial support from Takeda and Roche outside the submitted work., HAL UVSQ, Équipe, Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Cité (UPCité), Groupe hospitalier de la région de Mulhouse et Sud-Alsace, Département d'Oncologie Médicale [Centre René-Huguenin, Saint-Cloud], Hôpital René HUGUENIN (Saint-Cloud), Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois], and Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)

Subjects
[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, Male, [SDV]Life Sciences [q-bio], MESH: COVID-19 / complications, Comorbidity, MESH: Lymphoma, Non-Hodgkin / complications, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Risk Factors, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, MESH: Age Factors, Young adult, Research Articles, [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Aged, 80 and over, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, B-Lymphocytes, education.field_of_study, Lymphoma, Non-Hodgkin, MESH: SARS-CoV-2, Hazard ratio, Age Factors, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, Middle Aged, Combined Modality Therapy, MESH: Antigens, CD20 / immunology, 3. Good health, 030220 oncology & carcinogenesis, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Female, Rituximab, B-cell depleting immunotherapy, Immunotherapy, [SDV.IMM.IMM] Life Sciences [q-bio]/Immunology/Immunotherapy, Research Article, medicine.drug, Adult, medicine.medical_specialty, Population, lymphoma, [SDV.CAN]Life Sciences [q-bio]/Cancer, anti-CD20 therapy, Young Adult, MESH: Rituximab / administration & dosage, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, MESH: COVID-19 / mortality, Internal medicine, medicine, Humans, education, MESH: B-Lymphocytes / drug effects, Survival analysis, Aged, Proportional Hazards Models, Retrospective Studies, MESH: Aged, 80 and over, SARS-CoV-2, Proportional hazards model, business.industry, COVID-19, Retrospective cohort study, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, MESH: Combined Modality Therapy, Length of Stay, vaccination, Antigens, CD20, medicine.disease, Survival Analysis, Lymphoma, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Drug Resistance, Neoplasm, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, 030215 immunology
Abstract

International audience; Prolonged Covid-19 is an emerging issue for patients with lymphoma or immune deficiency. We aimed to examine prolonged length of in-hospital stay (LOS) due to Covid-19 among patients with lymphoma and assess its determinants and outcomes. Adult patients with lymphoma admitted for Covid-19 to 16 French hospitals in March and April, 2020 were included. Length of in-hospital stay was analyzed as a competitor vs death. The study included 111 patients. The median age was 65 years (range, 19–92). Ninety-four patients (85%) had B-cell non-Hodgkin lymphoma. Within the 12 months prior to hospitalization for Covid-19, 79 patients (71%) were treated for their lymphoma. Among them, 63 (57%) received an anti-CD20 therapy. Fourteen patients (12%) had relapsed/refractory disease. The median LOS was 14 days (range, 1–235). After a median follow-up of 191 days (3–260), the 6-month overall survival was 69%. In multivariable analyses, recent administration of anti-CD20 therapy was associated with prolonged LOS (subdistribution hazard ratio 2.26, 95% confidence interval 1.42–3.6, p < 0.001) and higher risk of death (hazard ratio 2.17, 95% confidence interval 1.04–4.52, p = 0.039). An age ≥ 70 years and relapsed/refractory lymphoma were also associated with prolonged LOS and decreased overall survival. In conclusion, an age ≥ 70 years, a relapsed/refractory lymphoma and recent administration of anti-CD20 therapy are risk factors for prolonged LOS and death for lymphoma patients hospitalized for Covid-19. These findings may contribute to guide the management of lymphoma during the pandemic, support evaluating specific therapeutic approaches, and raise questions on the efficacy and timing of vaccination of this particular population.

Published
2021
Full Text
View/download PDF

234. Leucémie lymphoïde chronique : de la biologie à la thérapeutique

Author

Jean-François Lesesve and Pierre Feugier

Subjects
03 medical and health sciences, Medical Laboratory Technology, 0302 clinical medicine, 030220 oncology & carcinogenesis, Biochemistry (medical), 030204 cardiovascular system & hematology, Analytical Chemistry
Abstract

Resume La leucemie lymphoide chronique (LLC) a vu ses modalites de prise en charge considerablement changer depuis une quinzaine d’annees. Un decryptage de plus en plus approfondi a permis de recenser des anomalies genetiques et moleculaires pouvant etre la cible de nouvelles therapeutiques. Des anomalies chromosomiques (deletion 17p avec mutation du gene TP53) ont un impact pronostic et therapeutique fort. Le bilan moleculaire est desormais indispensable avant initiation du traitement (statut mutationnel des genes des immunoglobulines IGVH). Cette strategie permettra d’orienter le choix entre immunochimiotherapie conventionnelle ou therapies ciblees. Les anomalies biologiques recemment trouvees sont presentees ici avec leur impact sur le traitement.

Published
2021
Full Text
View/download PDF

235. Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA

Author

Gandhi Damaj, Steven Le Gouill, Christophe Bonnet, Hervé Ghesquières, David Sibon, Marc André, Emmanuel Itti, Loïc Chartier, Françoise Kraeber-Bodéré, Luc Fornecker, Hervé Tilly, Vincent Ribrag, Franck Morschhauser, Jean-Philippe Jais, Caroline Bodet-Milin, Alina Berriolo-Riedinger, Krimo Bouhabdallah, Philippe Ruminy, Guillaume Cartron, Catherine Thieblemont, Remy Gressin, Reda Bouhabdallah, Corinne Haioun, Lucie Oberic, Thierry Jo Molina, René-Olivier Casasnovas, Pierre Feugier, Josette Brière, Thierry Lamy, and Hervé Maisonneuve

Subjects
medicine.medical_specialty, Immunology, CHOP, Antibodies, Monoclonal, Humanized, Biochemistry, Gastroenterology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, International Prognostic Index, Obinutuzumab, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Cyclophosphamide, business.industry, Cell Biology, Hematology, medicine.disease, Chemotherapy regimen, 3. Good health, Transplantation, chemistry, Doxorubicin, Vincristine, Positron-Emission Tomography, 030220 oncology & carcinogenesis, Prednisone, Vindesine, Rituximab, Lymphoma, Large B-Cell, Diffuse, business, Diffuse large B-cell lymphoma, 030215 immunology, medicine.drug
Abstract

Rituximab plus polychemotherapy is the standard of care in diffuse large B-cell lymphoma (DLBCL). GAINED, a randomized phase 3 trial, compared obinutuzumab to rituximab. Transplant-eligible patients (18-60 years) with an untreated age-adjusted International Prognostic Index (aaIPI) score ≥1 DLBCL were randomized (1:1) between obinutuzumab or rituximab and stratified by aaIPI (1; 2-3) and chemotherapy regimen (doxorubicin, cyclophosphamide, prednisone plus vindesine, bleomycin [ACVBP] or vincristine [CHOP]). Consolidation treatment was determined according to response to interim positron emission tomography (PET). Responders after cycle 2 and 4 (PET2−/PET4−) received immunochemotherapy. Responders after only cycle 4 (PET2+/4−) received transplantation. The primary objective was an 8% improvement (hazard ratio [HR] = 0.73; 80% power; α risk, 2.5%; 1-sided) in 2-year event-free survival (EFS) in the obinutuzumab arm. From September 2012, 670 patients were enrolled (obinutuzumab, n = 336; rituximab, n = 334). A total of 383 (57.2%) were aaIPI 2-3, 339 (50.6%) received CHOP. Median follow-up was 38.7 months. The 2-year EFS was similar in both groups (59.8% vs 56.6%; P = .123; HR = 0.88). The 2-year PFS in the whole cohort was 83.1% (95% confidence interval, 80% to 85.8%). PET2−/4− and PET2+/4− had similar 2-year progression-free survival (PFS) and overall survival (OS): 89.9% vs 83.9% and 94.8% vs 92.8%. The 2-year PFS and OS for PET4+ patients were 62% and 83.1%. Grade 3-5 infections were more frequent in the obinutuzumab arm (21% vs 12%). Obinutuzumab is not superior to rituximab in aaIPI ≥1 DLBCL transplant-eligible patients. This trial was registered at www.clinicaltrials.gov as #NCT01659099.

Published
2021
Full Text
View/download PDF

236. Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study

Author

Stamatoullas, Aspasia, primary, Ghesquières, Hervé, additional, Feugier, Pierre, additional, André, Marc, additional, Le Bras, Fabien, additional, Gac, Anne-Claire, additional, Borel, Cécile, additional, Gastinne, Thomas, additional, Quittet, Philippe, additional, Morschhauser, Franck, additional, Ribrag, Vincent, additional, Guidez, Stephanie, additional, Nicolas-Virelizier, Emmanuelle, additional, Berriolo-Riedinger, Alina, additional, Vander Borght, Thierry, additional, Edeline, Véronique, additional, and Brice, Pauline, additional

Published
2022
Full Text
View/download PDF

244. The effect of urine acidification on calcium oxalate relative supersaturation in cats

Author

Alexandre Feugier, Vincent Biourge, Esther Bijsmans, and Yann Queau

Subjects
Struvite, 040301 veterinary sciences, Sodium, Calcium oxalate, chemistry.chemical_element, Urine, Cat Diseases, Oxalate, 0403 veterinary science, Excretion, chemistry.chemical_compound, Animal science, Food Animals, Animals, Calcium Oxalate, 0402 animal and dairy science, 04 agricultural and veterinary sciences, Hydrogen-Ion Concentration, 040201 dairy & animal science, Urinary calcium, Diet, chemistry, Cats, Calcium, Urinary Calculi, Animal Science and Zoology, Base excess
Abstract

There is an apparent reciprocal relationship between magnesium ammonium phosphate (MAP, struvite) and calcium oxalate (CaOx) urolithiasis incidence rate in cats. The number of struvite uroliths submitted for analysis over the past 35 years has been decreasing, with an increase in CaOx urolith submissions. Commercial diets aimed to dissolve struvite uroliths are typically acidified, and it has been suggested that dietary acidification increases urinary calcium excretion and the risk of CaOx crystallization. The objective of this study was to assess the effect of urine acidification on the relative supersaturation (RSS) of CaOx in cats, as a representation of crystallization risk. Four diets were extruded to contain identical nutrient contents, but with gradual acidification (0, 0.6, 1.3 and 1.9% sodium bisulphate substituted sodium chloride in diets A, B, C and D respectively). Thirteen adult cats were fed each diet sequentially for a minimum of 10 days. Average urine pH was 6.4, 6.2, 6.0 and 5.9 on diets A, B, C and D respectively (p < 0.0001). Struvite RSS decreased on diets inducing more acidic urine pH (p < 0.0001). Urinary calcium excretion and concentration increased with diets inducing lower urine pH (p < 0.0001), but oxalate excretion and concentration decreased (p < 0.001). CaOx RSS was not different between diets (p = 0.63). These results suggest that a lower diet base excess and resulting urine pH to support struvite dissolution do not increase the risk for CaOx crystallization in the range of urine pH representative of most commercial feline diets. Long-term studies are needed to confirm this.

Published
2021
Full Text
View/download PDF

245. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

Author

Marek Trněný, Kathryn Humphrey, Nathalie A. Johnson, Sven de Vos, Gilles Salles, Farheen Mir, Richard Greil, Yanwen Jiang, Elizabeth Punnoose, Robin Gasiorowski, Arijit Sinha, Su Y. Kim, Caterina Patti, Emma Clark, Andrew D. Zelenetz, Jean-François Larouche, Nathalie Spielewoy, Divya Samineni, Alexandra Bazeos, Franck Morschhauser, Pierre Feugier, Pieternella J. Lugtenburg, Árpád Illés, Ian W. Flinn, and Hematology

Subjects
Oncology, medicine.medical_specialty, Vincristine, Clinical Trials and Observations, Immunology, Population, Phases of clinical research, Biochemistry, chemistry.chemical_compound, International Prognostic Index, immune system diseases, Internal medicine, hemic and lymphatic diseases, medicine, education, education.field_of_study, Venetoclax, business.industry, Cell Biology, Hematology, medicine.disease, Tolerability, chemistry, Rituximab, business, Diffuse large B-cell lymphoma, medicine.drug
Abstract

The phase 2 CAVALLI (NCT02055820) study assessed efficacy and safety of venetoclax, a selective B-cell lymphoma-2 (Bcl-2) inhibitor, with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line (1L) diffuse large B-cell lymphoma (DLBCL), including patients demonstrating Bcl-2 protein overexpression by immunohistochemistry (Bcl-2 IHC+). Eligible patients were ≥18 years of age and had previously untreated DLBCL, Eastern Cooperative Oncology Group performance status ≤2, and International Prognostic Index 2 to 5. Venetoclax 800 mg (days 4-10, cycle 1; days 1-10, cycles 2-8) was administered with rituximab (8 cycles) and cyclophosphamide, doxorubicin, vincristine, and prednisone (6-8 cycles) in 21-day cycles. Primary end points were safety, tolerability, and research_plete response (CR) at end of treatment (EOT). Secondary end points were progression-free survival (PFS) and overall survival. Comparative analyses used covariate-adjusted R-CHOP controls from the GOYA/BO21005 study, an appropriate contemporary benchmark for safety and efficacy. Safety and efficacy analyses included 206 patients. CR rate at EOT was 69% in the overall population and was maintained across Bcl-2 IHC+ subgroups. With a median follow-up of 32.2 months, trends were observed for improved investigator-assessed PFS for venetoclax plus R-CHOP in the overall population (hazard ratio [HR], 0.61; 95% confidence interval [CI], 0.43-0.87) and Bcl-2 IHC+ subgroups (HR, 0.55; 95% CI, 0.34-0.89) vs R-CHOP. Despite a higher incidence of grade 3/4 hematologic adverse events (86%), related mortality was not increased (2%). Chemotherapy dose intensity was similar in CAVALLI vs GOYA. The addition of venetoclax to R-CHOP in 1L DLBCL demonstrates increased, but manageable, myelosuppression and the potential of improved efficacy, particularly in high-risk Bcl-2 IHC+ patient subgroups. Key Points: • The phase 2 CAVALLI study assessed efficacy and safety of venetoclax + R-CHOP in patients with DLBCL, including Bcl-2+ subpopulations. • Venetoclax + R-CHOP showed potential for improved efficacy vs R-CHOP alone, supporting further investigation of venetoclax in Bcl-2+ DLBCL.

Published
2021
Full Text
View/download PDF

249. Clinical Research in Africa: Collaborative Project between Senegal and France to Improve the Diagnosis and Therapeutic Management of Adult Lymphoma Patients

Author

Sokhna Aïssatou Toure, Charline Moulin, Yankhoba Diop, Mourtalla Gueye, Mouhamadou Cherif Dial, Hervé Sartelet, Fatou Samba Ndiaye, Moussa Seck, Seynabou Fall, Alioune Badara Senghor, Awa Oumar Touré, Sabine Deltour, Blaise Felix Faye, Elimane Seydi Bousso, Alioune Badara Diallo, Mohamed Keita, Elhadji Daouda Niang, Nata Dieng, Catherine Thieblemont, Julien Broséus, Martine Raphael, Pierre Feugier, and Saliou Diop

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

250. Blinatumomab for Patients with Richter Syndrome: Final Results of the Phase 2 Blinart Trial from the Filo Group

Author

Romain Guieze, Loic Ysebaert, Damien Roos-Weil, Luc-Matthieu Fornecker, Emmanuelle Ferrant, Lysiane Molina, Thérèse Aurran-Schleinitz, Aline Clavert, Sophie de Guibert, Anne-Sophie Michallet, Alain Saad, Bernard Drenou, Philippe Quittet, Benedicte Hivert, Kamel Laribi, Julie Gay, Julien Broséus, Valérie Rouille, David Schwartz, Bruno Pereira, Alain Delmer, and Pierre Feugier

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results